PSHB GLP-1 coverage for weight loss 2027: what each plan’s brochure says, beside 2026
Federal Benefits Open Season for plan year 2027 runs November 9 to December 14, 2026.
* Three PSHB options end after 2026: GEHA High, MHBP Consumer, and UnitedHealthcare Postal East. If you are in one, choose a plan by December 14. See what ends- Every plan has to cover at least one.OPM requires every PSHB plan to cover at least one GLP-1 for weight loss and two oral anti-obesity drugs. Your plan’s drug list says which.
- On a GLP-1 for diabetes?OPM’s new program rule is for “treatment with anti-obesity medications” and does not name diabetes treatment. For diabetes use, your plan’s drug list sets the tier. Check Your Drug shows what each tier costs on every plan.
- New for 2027: an IBT program first.OPM’s rule: every plan must require documented participation in an evidence-based intensive behavioral therapy (IBT) program before and during treatment. OPM names no program, so each plan picks its own: brochures name Wondr Health, Noom Med, Teladoc’s weight program, and telephone coaching, and some run their own. On people already taking these drugs, the one brochure that says, the Rural Carrier plan, applies the rule to them too; the rest don’t say, so ask your plan. Open your plan below for its program, in its own words.
- What you pay depends on the plan.9 of the 12 brochures that state a price say you pay 50%. 19 state no price next to these drugs, so the drug list and tiers set it.
- 10 of 31 brochures changed these rules for 2027.Tap Changed for 2027 below to see only those.
- Have Medicare?By law, drugs used for weight loss aren’t Part D drugs, so a plan’s Medicare drug plan may treat them differently. What that means, and the With Medicare filter below.
From OPM Carrier Letter 2026-07, OPM’s 2027 Open Season highlights, and all 31 brochures OPM posted for 2027, read October 30, 2026. Counts are brochures, and one brochure can cover more than one plan option. Each plan’s brochure and drug list decide.
The price chips read the words next to GLP-1 and weight-loss drugs in each 2027 brochure. Some plans cap what you pay per fill. Counts are brochures. Mentions prior approval: the plan’s own GLP-1 passages say prior approval or step therapy applies; a plan whose passages don’t may still require it on its drug list.
Loading the brochure passages…
Search reads every passage and marks the words it found. A brochure that does not mention a drug may still cover it: the plan’s drug list decides. Open a plan to switch between 2027, 2026, and both years.
Open your plan above, then ask what its 2027 brochure says, in plain words, with the page numbers.
Novo Nordisk and Lilly run savings offers on Wegovy and Zepbound for some people whose plan covers the drug. Their own terms decide who qualifies and how much, and they can change them at any time, so we can’t tell you whether you qualify or what you’d pay. Novo’s Wegovy terms say the FEHB Program is not a government health care program “for purposes of this savings offer” and do not name PSHB. Lilly’s Zepbound terms name neither, and say the card ends December 31, 2026. Both exclude people enrolled in government programs such as Medicare (Lilly names Medicare Part D), Medicaid, TRICARE, and the VA, each in its own words. With Medicare, a plan’s Medicare drug plan is Part D coverage, so a card generally can’t be used there: see If you have Medicare.
Some brochures say how the plan treats them:
- GEHA Employee Organization: “We do not coordinate with drug coupon/copay cards.” (RI 71-021, page 80; RI 71-026, page 91)
- HealthPartners: “Any amounts paid or reimbursed by a third party, including but not limited to: point of service rebates, manufacturer coupons, debit cards or other forms of direct reimbursement to an enrollee for a product or service, will not apply toward your deductible.” (RI 73-915, page 23)
Before you use one, ask your plan whether it counts toward your deductible and out-of-pocket limit.
More for Open Season
What OPM requires of every plan
OPM requires every carrier to cover a range of FDA-approved anti-obesity medications on its formulary, including at least one from the GLP-1 class for weight loss and at least two oral options (OPM Carrier Letter 2026-07).
For 2027, all FEHB and PSHB carriers will require documented participation in an evidence-based intensive behavioral therapy (IBT) program both before and during treatment with anti-obesity medications (OPM’s 2027 Open Season highlights). OPM’s call letter adds that a member’s or provider’s attestation of earlier weight loss attempts should not bypass that requirement. Each plan’s brochure names its own program.
OPM says Postal Service annuitants and covered family members eligible for Medicare Part D get their drug coverage through the PSHB plan’s Part D plan (OPM’s PSHB program page). By law, “Agents when used for anorexia, weight loss, or weight gain” are not Part D drugs (Social Security Act section 1927(d)(2)(A), applied to Part D by section 1860D-2(e)(2)), so a plan’s Medicare drug plan can treat these drugs differently from its regular coverage. Separately, CMS’s Medicare GLP-1 Bridge gives eligible Part D enrollees certain GLP-1s for a $50 copay from July 1, 2026, to December 31, 2027, and CMS decides who qualifies.
That drug plan is Medicare Part D, and two things follow, in the brochures’ own words. The Medicare Income-Related Monthly Adjustment Amount (IRMAA) “is an amount you may pay in addition to your PSHB premium to enroll in and maintain Medicare prescription drug coverage” (RI 71-020, page 2, and every PSHB brochure). And on copay cards, NALC’s brochure cites the law: “Anti-Kickback Statute [42U.S.C. § 1320a-7b(b)] law prohibits people using Medicare drug coverage from using manufacturer coupons or discounts.” (RI 71-024, page 87)
18 plans have 2027 brochure passages on these drugs in their Medicare sections: tap With Medicare under Find your plan. 13 more describe a Medicare drug plan without naming these drugs, and say so when you open them.
How this page works
Every passage is the plan’s own wording. We read each PSHB brochure OPM publishes for 2026 and 2027 and kept the whole paragraph, list item, or table row wherever it names GLP-1 or anti-obesity drugs. A passage that sits in a table is the whole row, every cell under the brochure’s own column header, so what you pay and the conditions stay with the drug. A script then checked every passage, character by character, against a separate copy of the same brochure; nothing that fails that check is shown. The quotes are never shortened or reworded. The summary at the top and the price chips are ours, counted from those quotes, and each plan’s brochure and drug list decide.
Every passage links to its page. The source line names the brochure, the year, the section, and the page the brochure itself prints; the link opens OPM’s PDF of that brochure at that page so you can read it in context. Each plan also links its drug list (formulary) and its own site.
What this page does not cover. Whether a specific drug is on a plan’s formulary and at which tier, prior authorization and step therapy criteria, quantity limits, and changes a plan makes to its drug list during the year all live in the formulary and the plan’s own pages, not always in the brochure. FEHB plans are a separate program: see FEHB GLP-1 coverage. Brochures that do not name these drugs are shown as such, with the formulary link, rather than filled in.
Before you enroll
OPM’s files and plan brochures don’t always match. We use what’s publicly available and do our best to catch the differences. StandWatch is independent, is not affiliated with the U.S. Postal Service, and does not act for OPM or any plan.
Not medical advice. Whether a GLP-1 is right for you is a question for your doctor. This page shows what each plan’s brochure says it covers.
The plan decides coverage and claims under its brochure, and your employing office handles eligibility and enrollment. If a plan denies a claim, the brochure’s disputed claims section shows how to ask the plan to reconsider and then ask OPM to review it. Every 2027 brochure says: “This brochure is the official statement of benefits.” Each plan’s formulary lists the covered drugs. Where this page and either one disagree, theirs governs. Call the plan before you enroll if a drug matters to you.
No affiliation, no ranking. StandWatch is not affiliated with, endorsed by, or acting for OPM or any plan, and lists plans by name, not by rank. Nothing here is a recommendation to select, keep, or drop a plan, or medical, insurance, financial, or legal advice. The full educational-purpose statement.
Sources
Each plan’s 2026 and 2027 brochure as OPM publishes it at opm.gov (HTML and PDF), read October 30, 2026. OPM Federal Benefits Open Season Highlights, Plan Year 2027. OPM Carrier Letter 2026-07. OPM: Medicare and FEHB. Social Security Act section 1927 and section 1860D-2. CMS: Medicare GLP-1 Bridge. Drug makers’ savings terms: Wegovy, Zepbound. Plan drug lists and sites: the addresses in OPM’s 2027 PSHB plan key.